Administer GLP-1 receptor agonists to individuals with T2DM and either existing ASCVD or those predisposed to ASCVD, as these agents have demonstrated efficacy in lowering the occurrence of stroke [37]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.